Leukemia Research
Volume 27, Issue 7 , Pages 571-573 , July 2003

Angiogenesis in hematology: a field of active research

Received 22 November 2002

References 

  1. Weidner N, Folkman J. Tumor vascularity as a prognostic factor in cancer. In: De Vita V, Helmann S, Rosenberg SA, editors. Important advances in oncology. Lippincott-Raven; 1996. p. 167–90.
  2. Mangi MH, Newland AC. Angiogenesis and angiogenic mediators in haematological malignancies. Br. J. Haematol. 2000;111:43–51
  3. Giustolisi R, Di Raimondo F. Angiogenesis in hematology. Acta Haematol. 2001;4:147–220
  4. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 1997;150:815–821
  5. Vacca A, Ribatti D, Presta M, Monischetti M, Iurlaro M, Ria R, et al.  Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064–3073
  6. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas. An immunohistochemical and ultrastructural study. Eur. J. Haematol. 1996;56:45–53
  7. Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, et al.  Angiogenesis in myelodysplastic syndromes. Br. J. Cancer. 1999;81:1398–1401
  8. Korkolopoulou P, Apostolidou E, Pavlopoulos PM, Kavantzas N, Vyniou N, Thymara I, et al.  Prognostic evaluation of the microvascular network in myelodysplastic syndromes. Leukemia. 2001;15:1369–1376
  9. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309–313
  10. Padrò T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, et al.  Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637–2644
  11. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, et al.  Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood. 2002;100:3344–3351
  12. Lundberg LG, Lerner R, Sundelin P, Rogers R, Folkman J, Palmblad J. Bone marrow in polycytemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol. 2000;157:15–19
  13. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, et al.  Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer. 1996;32A:2474–2484
  14. Tung-Ping Poon R, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001;19:1207–1225
  15. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671–674
  16. Ferrara N, Davis-Smyth T. Biology of vascular endothelial growth factor. Endocrinol. Rev. 1997;18:4–25
  17. Dvorak H. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002;20:4368–4380
  18. Kim J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vitro. Nature. 1993;362:841–844
  19. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al.  Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol. 1992;119:629–641
  20. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, et al.  Agiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245
  21. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Giustolisi G, Floridia PM, et al.  Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica. 2000;85:800–805
  22. Jelkmann W. Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin. Chem. 2001;47:617–623
  23. Di Raimondo F, Azzaro MP, Palumbo GA, Bagnato S, Stagno F, Giustolisi G, et al.  Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia. 2001;15:976–980
  24. Molica S, Vitelli G, Levato D, Gandolfo GM, Liso V. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leucemia. Br. J. Haematol. 1999;107:605–610
  25. Salven P, Orpana A, Teerhenovi L, Joensuu H. Simultaneous elevation in the serum concentrations of the angiogenic growth factor VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood. 2000;96:3712–3718
  26. Borset M, Hjort-hansen H, Seidel C, Sundan A, Waage A. Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood. 1996;88:3998–4004
  27. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, et al.  Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001;15:1165–1170
  28. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, et al.  Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 2001;276:3222–3230
  29. Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000;60:203–212
  30. Shalaby F, Ho J, Stanford WL, Fischer KD, Schuh AC, Schwartz L, et al.  A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981–990
  31. Pelosi E, Valtieri M, Coppola S, Botta R, Gabbianelli M, Lulli V, et al.  Identification of the hemangioblast in postnatal life. Blood. 2002;100:3203–3208
  32. Zeng H, Dvorak HF, Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 2001;276:26969–26979
  33. Bernatchez PN, Rollin S, Soker S, Sirois MG. Relative effects of VEGF-A and VEGF-C on endothelial cell proliferation, migration and PAF synthesis: role of neuropilin-1. J. Cell Biochem. 2002;85:629–639
  34. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728–733
  35. Pons E, Uphoff CC, Drexler HG. Expression of hepatocyte growth factor and its receptor c-met in human leukemia-lymphoma cell lines. Leuk. Res. 1998;22:797–804
  36. Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al.  Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875
  37. Dias S, Hattori K, Zhu Z, Heissig B, Choy M, Lane W, et al.  Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 2000;106:511–521
  38. Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99:2179–2184
  39. Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, et al. Clinical relevance of VEGF receptor 1 and 2 in patients with chronic myelogenous leukemia, Leuk Res 27.
  40. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996;87:3336–3343
  41. Dias S, Lane WJ, Wu Y, Choy M, Peichev M, Chadburn A, et al. Neutralizing MoAb to VEGF receptors inhibit proliferation and migration of a subset of human leukemias through interaction with VEGFR-2(KDR) and VEGFR-1(FLT-1). In: Proceedings of the 41st Meeting of the Am. Soc. Hemat. Blood 1999;94(Suppl 1):2754.
  42. Dias S, Hattori K, Heissig B, Zhu Z, Wu W, Witte L, et al.  Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. PNAS. 2001;98:10857–10862

PII: S0145-2126(02)00328-4

doi: 10.1016/S0145-2126(02)00328-4

Leukemia Research
Volume 27, Issue 7 , Pages 571-573 , July 2003

Article Tools